Larvol Delta - Avadel-Pharmaceuticals-announces-FDA-agreement-to-reduce-the-sample-size-for-the-ongoing-pivotal-phase-3-study-for-oncenightly-FT218-Full-enrollment-now-expected-by-end-of-2019

sodium oxybate ER (FT218) - Avadel

https://www.globenewswire.com/news-release/2019/09/23/1919054/0/en/Avadel-Pharmaceuticals-Announces-FDA-Agreement-to-Reduce-the-Sample-Size-for-the-Ongoing-Pivotal-Phase-3-Study-for-Once-Nightly-FT218-Full-Enrollment-Now-Expected-by-End-of-2019.html

Sep 23, 2019

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next